Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
J ANTIINFECTIVES FOR SYSTEMIC USE
J05 ANTIVIRALS FOR SYSTEMIC USE
J05A DIRECT ACTING ANTIVIRALS
J05AJ Integrase inhibitors
J05AJ01 Raltegravir
D07133 Raltegravir potassium (JAN/USAN) <JP/US>
USP drug classification [BR:br08302]
Antivirals
Anti-HIV Agents, Integrase Inhibitors (INSTI)
Raltegravir
D07133 Raltegravir potassium (JAN/USAN)
Therapeutic category of drugs in Japan [BR:br08301]
6 Agents against pathologic organisms and parasites
62 Chemotherapeutics
625 Antivirals
6250 Antivirals
D07133 Raltegravir potassium (JAN/USAN)
Drug groups [BR:br08330]
Antiviral
DG03107 Anti-HIV agent
DG03135 HIV integrase inhibitor
DG00666 Raltegravir
D07133 Raltegravir potassium
Metabolizing enzyme substrate
DG02924 UGT substrate
DG03183 UGT1A1 substrate
DG00666 Raltegravir
D07133 Raltegravir potassium
Drug classes [BR:br08332]
Antiviral
DG03107 Anti-HIV agent
D07133 Raltegravir potassium
Antimicrobials [BR:br08307]
Antivirals
Genome replication inhibitor
HIV integrase inhibitor
D07133 Raltegravir potassium (JAN/USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D07133
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D07133
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D07133
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D07133
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D07133
Drug groups [BR:br08330]
Antiviral
DG03107 Anti-HIV agent
DG03135 HIV integrase inhibitor
DG00666 Raltegravir
Metabolizing enzyme substrate
DG02924 UGT substrate
DG03183 UGT1A1 substrate
DG00666 Raltegravir
Antimicrobials abbreviations [BR:br08327]
Antivirals
Genome replication inhibitor
HIV integrase inhibitor
DG00666 Raltegravir